Share |

biotech

Dr. David Brown: How Viagra opened the doors to machine learning innovation

March 17, 2023

In an exclusive interview with Campden FB, Dr. David Brown talks about his passion for entrepreneurialism, the mind-blowing benefits of machine learning and how big pharma needs a change in mindset…

Throughout his storied career, Dr. David Brown has made significant contributions to medical research within the pharmaceutical industry, but perhaps his most famous innovation came about through a chance observation when the angina medication he was working on had unexpected applications.

While working for Pfizer, he was named co-inventor on the patent for Viagra and, for eight years, led the team that developed the hugely successful erectile dysfunction medication into one of the bonanza breakthroughs of the century.

Aleksandr “Shurick” Agapitov: Creating a new frontier for investors and entrepreneurs

March 13, 2023

In an exclusive interview with Campden FB, the man responsible for building a $3 billion video game payments powerhouse with his company Xsolla discusses the challenges and opportunities of the internet’s next great step forward.

Since building a $3 billion video game payments powerhouse with his company Xsolla, Aleksandr “Shurick” Agapitov is now responsible for giving the developer community the tools they need to compete and succeed in the hyper-competitive video game arena.

How the Arnault family is leading the way in planning for succession

January 26, 2023

While the succession plans of many ultra-high-net-worth families are, according to Campden Wealth’s European Family Office Report 2022, only informally agreed, unwritten or still in the process of development, the family-owned company running luxury goods giant LVMH is running on clear and transparent lines of communication, says Stuart Hatcher.

While the succession plans of many ultra-high-net-worth families are, according to Campden Wealth’s European Family Office Report 2022, only informally agreed (19%), unwritten (21%) or still in the process of development (14%), the family running owned company which operates luxury goods giant LVMH is running on clear and transparent lines of communication.

European Family Office Report: Uncertain times lead to certain measures with an increased focus on private equity

January 16, 2023

Campden Wealth reveals European family offices are proactively adopting inflation-mitigating investment strategies as economic uncertainty looks to continue for the foreseeable future.

After a tumultuous few years and with even more uncertainty set for the foreseeable future, Europe-based family offices are proactively adopting inflation-mitigating investment strategies, according to Campden Wealth’s new European Family Office Report 2022.

Why are family offices increasing sustainable investing?

November 30, 2022

An increased consideration of environmental, social and governance (ESG) factors, innovations in technology and a next-gen-driven desire to do better for the world are seen as motivating factors for family offices increasing their commitment to sustainable investment, according to Campden Wealth and Raffles Family Office’s Asia-Pacific Family Office Report 2022.

Asia-Pacific Family Office Report: Inflation impact forces a focus on alternative investments, real estate and equities

November 30, 2022

In the new Asia-Pacific Family Office Report 2022, Campden Wealth and Raffles Family Office reveal Asia-Pacific family offices are on the lookout for investment opportunities across new and old asset classes, as portfolio diversification and alternative investments become top priorities.

Family offices based in the Asia-Pacific region are increasingly adopting strategies to mitigate the adverse impact of inflation, according to the new Asia-Pacific Family Office Report 2022 by Campden Wealth and Raffles Family Office.

Why are family offices in a cautious climate making the move to ‘risky’ digital assets?

November 17, 2022

While the unsettling multiple whammy of COVID-19 pandemic, a global inflation spike, rising interest rates, geopolitical perils and potential looming recession have driven a reduction in investment risk towards a more conservative and balanced strategy, Family Offices have nevertheless developed a taste for tech, according to Campden Wealth and RBC's The North America Family Office Report 2022.

While the unsettling multiple whammy of COVID-19 pandemic, a global inflation spike, rising interest rates, geopolitical perils and potential looming recession have driven a reduction in investment risk towards a more conservative and balanced strategy, North American Family Offices have nevertheless developed a taste for tech.

North America Family Office Report 2022: Risk reduction, a focus on private equity and a move towards sustainable investing

November 16, 2022

Campden Wealth and Royal Bank Of Canada reveal North American family offices outperformed their global peers in the new North America Family Office Report 2022. Despite a reduction in investment risk, family offices remain committed to private equity and new technologies.

North American family offices have continued to see their collective wealth and investment returns grow despite the aftershocks of the COVID-19 pandemic and subsequent hike in inflation, interest rates and geopolitical risks, according to the North America Family Office Report 2022 by RBC and Campden Wealth.

Further innovations in MedTech to be presented at the 32nd MTi Forum

July 6, 2022

Companies developing pioneering oesophageal drug-delivery systems, innovative bio-wearables and a venture builder for MedTech and biotech advances will exclusively present in-person as Campden Wealth returns to Lausanne, Switzerland, for the 32nd edition of the MedTech Investing Europe Forum (MTi) on July 12 and 13.

The disruptive medtech company aiming to minimise patients’ need for invasive mechanical ventilation intervention

April 4, 2022

INSPIRA is developing a cost-effective respiratory support system which will function as an artificial lung for deteriorating respiratory patients. Ahead of presenting at the 32nd edition of the MedTech investing (MTi) forum on June 6 and 7, president and co-founder Joe Hayon explains the benefits and potential future applications of the system.

INSPIRA is an innovative medical device company which is developing the ART system, a cost-effective early extracorporeal respiratory support system which will function as an artificial lung for deteriorating respiratory patients.

The ART system utilises a new approach based on hemo-protective technology aimed at rebalancing oxygen saturation levels while patients are awake and breathing, potentially minimising the patient's need for invasive mechanical ventilation intervention.